Table 2

Characteristics of early and late neurosyphilis (Alberta, 1973 to March 2017; n=250)

Early neurosyphilisLate neurosyphilisComparison of Early and Late p-Value
Asymptomatic (n=28)Symptomatic (n=105)Total (n=133)P valueAsymptomatic (n=47)Symptomatic (n=70)Total (n=117)P value
Median age (IQR)40 (32–46)47 (39–55)44 (36–54)0.0245 (32–65)64 (53–75)58 (45–70)<0.001<0.001
Gender
 Female8 (28.6)12 (11.4)20 (15.0)0.026 (12.8)15 (21.4)21 (17.9)0.230.54
 Male20 (71.4)93 (88.6)113 (85.0)41 (87.2)55 (78.6)96 (82.1)
Ethnicity
 Indigenous6 (21.4)6 (5.7)12 (9.0)0.0016 (12.8)3 (4.3)9 (7.7)0.44<0.001
 Caucasian10 (35.7)78 (74.3)88 (66.2)14 (29.8)23 (32.9)37 (31.6)
 Other3 (10.7)4 (3.8)7 (5.3)16 (34.0)27 (38.6)43 (36.8)
 Unknown9 (32.1)17 (16.2)26 (19.5)11 (23.4)17 (24.3)28 (23.9)
Municipality
 Calgary9 (32.1)32 (30.5)41 (30.8)0.6210 (21.3)22 (31.4)32 (27.4)0.460.59
 Edmonton15 (53.6)48 (45.7)63 (47.4)28 (59.6)35 (50.0)63 (53.8)
 Other4 (14.3)25 (23.8)29 (21.8)9 (19.1)13 (18.6)22 (18.8)
Country of birth
 Canada16 (57.1)56 (53.3)72 (54.1)0.2323 (48.9)16 (22.9)39 (33.3)0.01<0.001
 Outside of Canada5 (17.9)9 (8.6)14 (10.5)17 (36.2)36 (51.4)53 (45.3)
 Unknown7 (25.0)40 (38.1)47 (35.3)7 (14.9)18 (25.7)25 (21.4)
Decade of diagnosis
 1970s1 (3.6)1 (1.0)2 (1.5)0.0014 (8.5)1 (1.4)5 (4.3)0.29<0.001
 1980s6 (21.4)3 (2.9)9 (6.8)13 (27.7)15 (21.4)28 (23.9)
 1990s3 (10.7)5 (4.8)8 (6.0)6 (12.8)9 (12.7)15 (12.8)
 2000s8 (28.6)28 (26.7)36 (27.1)4 (8.5)20 (28.6)24 (20.5)
 2010s10 (35.7)68 (64.8)78 (58.6)20 (42.6)25 (35.7)45 (38.5)
Sexual partners
 Heterosexual12 (42.9)46 (43.8)58 (43.6)1.0030 (63.8)38 (54.3)68 (58.1)0.002<0.001
 Same sex14 (50.0)52 (49.5)66 (49.6)11 (23.4)5 (7.1)16 (13.7)
 Unknown2 (7.1)7 (6.7)9 (6.8)6 (12.8)27 (38.6)33 (28.2)
HIV status
 Negative5 (17.9)68 (64.8)73 (54.9)<0.00119 (40.4)27 (38.6)46 (39.3)0.31<0.001
 Positive17 (60.7)30 (28.6)47 (35.3)8 (17.0)6 (8.6)14 (12.0)
 Unknown6 (21.4)7 (6.7)13 (9.8)20 (42.6)37 (52.9)57 (48.7)
Treatment
 Penicillin G22 (78.6)82 (78.1)104 (78.2)0.8721 (44.7)63 (90.0)84 (71.8)<0.0010.43
 Ceftriaxone3 (10.7)14 (13.3)17 (12.8)12 (25.5)5 (7.1)17 (14.5)
 Other3 (10.7)9 (8.6)12 (9.0)14 (29.8)2 (2.9)16 (13.7)